|
abrdn Life Sciences Investors is a closed-end fund that seeks long-term capital appreciation by investing primarily in securities of life sciences companies. The fund invests primarily in equity and related securities, including common stock, preferred stock, convertible debt, limited partnership interests, and warrants, of U.S. and foreign companies principally engaged in the development, production, or distribution of products or services related to scientific advances in life sciences. These life sciences sectors include biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices, supplies, and other healthcare-related subsectors. The fund also invests in companies involved in agriculture and environmental management. The investment strategy targets companies believed to have significant potential for above-average, long-term growth in revenues and earnings, ranging from emerging growth companies at the research and development stage to large, well-known companies with existing products. The fund invests in venture capital and other restricted securities, and in foreign securities, primarily located in Western Europe, Canada, and Japan. The fund may also engage in the purchase and sale of put or call options and financial futures contracts. Summarised from the fund's shareholder report or prospectus, filed Dec 2025 |
Industry Asset Management | Homepage abrdnhql.com |
| Sector Financial Services | IR page — | |
|
Tags
closed-end fund, biotechnology, pharmaceuticals, medical devices, healthcare information technology, agriculture, environmental management, venture capital, emerging growth companies, global equities, abrdn Life Sciences Investors, Restricted Securities, Foreign Securities
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 568.63M |
| Market cap (USD) | $ 568.63M |
| P/E | 2.82 |
| PEG | — |
| P/BV | 1.01 |
| P/S | 293.35 |
| Discount/premium to NAV | -10.6% |
| P/OCF | 17.93 |
| P/FCF | 17.93 |
| Dividend yield | 9.7% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 17.6% |
| ROI | 16.7% |
| ROIC | -0.49% |
| Profit margin | 4,415.7% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 29.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Nov 6, 2023 | Renamed | TEKLA LIFE SCIENCES INVESTORS → abrdn Life Sciences Investors |
| Oct 15, 2014 | Renamed | H&Q LIFE SCIENCES INVESTORS → TEKLA LIFE SCIENCES INVESTORS |
ETFs Holding abrdn Life Sciences Investors Shares of Beneficial Interest
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| FCEF | 1.75% | 76,831 | $ 1.368M | Nov 16, 2026 |